Page last updated: 2024-09-05

lapatinib and Benign Neoplasms, Brain

lapatinib has been researched along with Benign Neoplasms, Brain in 117 studies

Research

Studies (117)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (11.11)	29.6817
2010's	90 (76.92)	24.3611
2020's	14 (11.97)	2.80

Authors

Authors	Studies
Ansari, K; Bhan, A; Chen, MY; Jandial, R	1
Bachelot, T; Bailleux, C; Darlix, A; Jacot, W	1
Chen, T; He, Y; Lu, H; Pang, Z; Wang, Y	1
Agostinetto, E; Awada, A; Bruzzone, M; Ceppi, M; Danielli, L; de Azambuja, E; Kotecki, N; Lambertini, M; Martins-Branco, D; Nader-Marta, G	1
Alley, SC; Bao, X; Jiang, J; Kumar, V; Lee, AJ; Li, J; Peterson, S	1
Badwe, R; Bajpai, J; Bhargava, P; Budrukkar, A; Desai, S; Ghosh, J; Gulia, S; Gupta, S; Joshi, S; Kannan, S; Nair, N; Pathak, R; Patil, A; Popat, P; Rath, S; Rathnasamy, N; Sarin, R; Shenoy, R; Shet, T; Wadasadawala, T	1
Lin, NU	1
Antao, V; Lamarre, N; Montemurro, F; Peña-Murillo, C; Sanglier, T; Shim, J	1
Aydiner, A; Dogan, I; Ibis, K; Kizildag, I; Özkurt, S; Saip, P; Vatansever, S	1
Gangemi, E; Greco, C; Ippolito, E; La Cesa, A; Matteucci, P; Ramella, S; Santini, D; Santo, B; Silipigni, S	1
Cao, J; Du, Y; Hu, X; Lin, M; Lin, Y; Tao, Z; Wang, B; Wang, L; Zhang, J; Zhang, S	1
Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bonazzina, E; Bonoldi, E; Cappello, G; Cassingena, A; Ciardiello, F; Fenocchio, E; Ghezzi, S; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Mauri, G; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Tosi, F; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Zagonel, V	1
Aldape, K; Armstrong, TS; Gerstner, ER; Gilbert, MR; Lieberman, F; Mendoza, T; Mikkelsen, T; Omuro, A; Robins, HI; Vera, E; Wen, PY; Wu, J; Yuan, Y	1
Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG	1
Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A	1
Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K	1
Barni, S; Borgonovo, K; Cabiddu, M; Ghidini, M; Ghilardi, M; Lonati, V; Petrelli, F; Tomasello, G	1
Haeno, H; Michor, F; Stein, S; Vivanco, I; Zhao, R	1
Hirata, M; Nezasa, KI; Shinonome, S; Tanaka, H; Tanaka, Y; Torii, M	1
Beal, K; Diab, A; Hudis, CA; McArthur, HL; Morikawa, A; Patil, S; Seidman, AD; Wang, R; Yang, J	1
Duchnowska, R; Jassem, J; Loibl, S	1
Abraham, J; Ahluwalia, MS; Angelov, L; Barnett, GH; Budd, GT; Chao, ST; Kim, JM; Kotecha, R; Miller, JA; Mohammadi, AM; Moore, H; Murphy, ES; Peereboom, DM; Suh, JH; Vogelbaum, MA	1
Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Juloori, A; Kotecha, R; Miller, JA; Mohammadi, AM; Murphy, ES; Parsai, S; Peereboom, DM; Suh, JH; Vogelbaum, MA	1
Jing, Y; Liu, F; Liu, Y; Lu, Z; Lv, J; Shao, YW; Sun, A; Tao, F; Wang, W; Wu, X; Xu, G; Ye, M	1
Kümler, I; Larsen, PB; Nielsen, DL	1
Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH	1
Ahmed, S; Ammannagari, N; Bravin, EN; Patel, A	1
Azria, D; Braccini, AL; Ferrero, JM; Jacot, W; Romieu, G; Thezenas, S	1
Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR	1
Aldape, KD; Ding, Z; Guo, H; Huang, S; Huang, WC; Lowery, FJ; Sahin, AA; Steeg, PS; Wang, H; Yu, D; Zhang, C; Zhang, L; Zhang, S	1
Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P	1
Awada, A; Buttice, A; Cardoso, F; D'Hondt, V; de Azambuja, E; Devriendt, D; Gil, T; Lalami, Y; Lebrun, F; Lemort, M; Moulin, C; Paesmans, M; Piccart-Gebhart, M; Rossari, J; Sotiriou, C; Zardavas, D	1
Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S	1
Bartolotti, M; Brandes, AA; Franceschi, E	1
Bastida, CC; Falchook, GS; Jiang, Y; Kurzrock, R; Moulder, SL; Wheler, JJ	1
Bellon, JR; Come, SE; Eichler, AF; Eisenberg, E; Freedman, RA; Gelman, RS; Harris, GJ; Henderson, MA; Ligibel, JA; Lin, NU; Macdonald, SM; Mahadevan, A; Mayer, EL; Moy, B; Ramakrishna, N; Storniolo, AM; Winer, EP; Younger, J	1
Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S	1
Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Xi, Z; Zhang, Q	1
Şendur, MA; Uncu, D; Zengin, N	1
Cardinali, B; Crinò, L; Del Mastro, L; Foglietta, J; Gori, S; Inno, A; Lunardi, G	1
Cao, KI; Kirova, YM	1
Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S	1
Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ	1
Altundag, K; Arslan, C; Dizdar, O	2
Shawky, H; Tawfik, H	1
Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y	1
Fujisawa, T; Hayashi, N; Honda, Y; Hozumi, Y; Ishida, M; Iwata, H; Kanbayashi, C; Kondo, N; Masuda, N; Matsui, A; Naito, Y; Nakamura, R; Niikura, N; Oshitanai, R; Saji, S; Takashima, S; Tsuneizumi, M; Watanabe, K; Yamauchi, H; Yasojima, H	1
Patil, A; Sherbet, GV	1
Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W	1
Dittrich, C; Fridrik, MA; Gampenrieder, SP; Greil, R; Hufnagl, C; Lang, A; Mlineritsch, B; Petru, E; Pircher, M; Ressler, S; Rinnerthaler, G; Thaler, J; Ulmer, H; Weltermann, A	1
Marchetti, D; Ngo, JA; Wetzel, MD; Zhang, L	1
Bachelot, T; Bernard-Marty, C; Bonneterre, J; Conforti, R; Le Rhun, E; Taillibert, S	1
Bartsch, R; Bergen, ES; Berghoff, AS; Preusser, M; Rudas, M	1
Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L	1
Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N	1
Bandai, Y; Ijichi, M; Kusaka, K; Sakata, H; Shibasaki, M; Tanabe, A; Toda, T	1
Esteva, FJ; Teplinsky, E	1
Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M	1
Bachelot, T; Barriere, J; Bono, P; Ciruelos, E; Cortés, J; Dieras, V; Espié, M; Hurvitz, S; Joensuu, H; Kellokumpu-Lehtinen, PL; Kim, SB; Le Rhun, E; Nabholtz, JM; Ould-Kaci, M; Piacentini, F; Ro, J; Roux, F; Schneeweiss, A; Sohn, JH; Taguchi, J	1
Griggs, JJ; Hayes, DF; Henry, NL; Kidwell, KM; Merajver, SD; Murthy, P; Schott, AF; Smerage, JD; Van Poznak, CH; Wicha, MS	1
Dermawan, JK; Gurova, KV; Hitomi, M; Lathia, JD; Purmal, AA; Rich, JN; Sandlesh, P; Silver, DJ; Sloan, AE; Stark, GR; Venere, M; Wu, Q	1
Jiang, T; Jiang, X; Pang, X; Pang, Z; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zhao, J; Zheng, X	1
Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V	1
Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Kotecha, R; Miller, JA; Mohammadi, AM; Murphy, ES; Peereboom, DM; Suh, JH; Vogelbaum, MA	1
Benowitz, S	1
Bronder, JL; Feigenbaum, L; Gril, B; Herring, JM; Liewehr, DJ; Merino, MJ; Palmieri, D; Rubin, SD; Steeg, PS; Steinberg, SM; Vega-Valle, E	1
Belkacémi, Y; Kuten, A	1
Glantz, M; Melisko, ME; Rugo, HS	1
Ma, CD; Shen, KW; Shen, ZZ	1
Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D	1
Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S	1
Belanger, K; Easaw, J; Eisenhauer, E; Forsyth, P; Kamel-Reid, S; Mason, W; McIntosh, L; Schaiquevich, P; Stewart, C; Thiessen, B; Tsao, M	1
Bravo Marques, JM	1
Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D	1
Bedard, PL; de Azambuja, E; Devriendt, D; Lossignol, D; Piccart-Gebhart, MJ; Tomasello, G	1
Akhavan, D; Bensinger, SJ; Cloughesy, TF; Dang, J; DeAngelis, LM; Guo, D; Hock, MB; Horvath, S; Huang, TT; Iwanami, A; Kofman, AA; Kuga, D; Kuhn, JG; Lin, KY; Mehta, MP; Mellinghoff, IK; Mischel, PS; Prados, MD; Prins, RM; Robins, HI; Soto, H; Vinters, HV; Watson, AD; Wen, PY; Yong, WH; Zhu, S	1
Pikó, B	1
Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S	1
Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A	1
Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A	1
Katano, M; Morisaki, T; Nakafusa, Y; Nakashima, Y; Onishi, H; Yokohata, K	1
Addeo, R; Caraglia, M	1
Callahan, R; Hurvitz, S	1
Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sophie, S; Zanetti, A	1
Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D	1
Castellino, S; Gril, B; Hua, E; Lockman, J; Lockman, PR; Mittapalli, RK; Palmieri, D; Polli, JW; Rubin, SD; Rudraraju, V; Samala, R; Smith, QR; Steeg, PS; Taskar, KS; Thorsheim, HR	1
Akhavan, D; Amzajerdi, AN; Babic, I; Chakravarti, A; Cloughesy, TF; Dang, J; Deangelis, LM; Dejesus, J; Gini, B; Guo, D; Hong, C; Huang, TT; Iwanami, A; James, CD; Kuga, D; Lisiero, DD; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nathanson, D; Prados, MD; Prins, RM; Reinitz, F; Robins, HI; Soto, H; Tanaka, K; Tontonoz, P; Wen, PY; Youssef, M; Zhu, S	1
Lee, SH	1
Azim, HA	1
Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S	1
Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E	1
Alici, S; Arslan, UY; Bilici, M; Boruban, C; Buyukberber, S; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Mert, AG; Ozkan, M; Suner, A; Tarhan, MO; Unal, OU; Urakci, Z; Yaman, S; Yildiz, R	1
Rudà, R; Soffietti, R; Trevisan, E	1
Chung, JS; Im, YH; Kim, S; Kim, TY; Moon, H; Park, S; Rha, SY; Ro, J; Santillana, S	1
Lim, E; Lin, NU	1
Cornelio, GH; Devi, BC; Khorprasert, C; Kim, SB; Kim, TY; Kobayashi, M; Landis, SH; Lee, SC; Moon, H; Park, YH; Ro, J; Sohn, JH; Sutandyo, N; Wong, DW; Yap, YS; Yeoh, EM	1
Jain, A; Ryan, PD; Seiden, MV	1
Booth, L; Chen, CS; Cruickshanks, N; Dent, P; Grant, S; Ridder, T	1
Fujiwara, Y; Ito, Y; Iwata, H; Katsura, K; Narabayashi, M; Saji, S; Sasaki, Y; Usami, S	1
Ager, E; Chung, E; Duyverman, AM; Eichler, AF; Engelman, JA; Farrar, CT; Fukumura, D; Goel, S; Hiddingh, L; Huang, Y; Incio, J; Jain, RK; Kamoun, W; Kodack, DP; Lussiez, A; Mahmood, S; Snuderl, M; Song, Y; Tannous, BA; Yamashita, H	1
Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G	1
Bartsch, R; Preusser, M	1
Fujita, Y; Goto, M; Hamaoka, A; Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Shouji, M; Taguchi, T; Umeda, Y	1
Andreu, X; Baena, C; Bronchud, MH; Castillo, S; Escriva de Romaní, S; Esquius, J; Fernández, A; Julia, JC; Mourelo, S; Murillo, J; Romero, R	1
Nieder, C	1
Basavalingaiah, A; Madhusudhan, N; Revannasiddaiah, S; Susheela, SP	1
Bachelot, T; Campone, M; Cropet, C; Diéras, V; Jimenez, M	1
Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D	1
Cho, N; Hayashi, M; Yomo, S	1
Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY	1
Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R	1
Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY	1
Hochberg, FH; Kirsch, DG	1
Hatake, K	1
Bullitt, E; Burstein, HJ; Carey, LA; Come, SE; Crawford, A; Ewend, M; Gelman, R; Harris, GJ; Henson, JW; Hochberg, F; Kasparian, E; Kirsch, DG; Li, X; Lin, NU; Liu, MC; Van den Abbeele, AD; Winer, EP; Younger, J	1

Reviews

27 review(s) available for lapatinib and Benign Neoplasms, Brain

Article	Year
Bulletin du cancer, 2021, Volume: 108, Issue:11S Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab	2021
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. ESMO open, 2022, Volume: 7, Issue:3 Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors	2022
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies. JNCI cancer spectrum, 2021, Volume: 5, Issue:4 Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic	2021
The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. European journal of cancer (Oxford, England : 1990), 2017, Volume: 84 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome	2017
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer treatment reviews, 2018, Volume: 67 Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2	2018
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer treatment reviews, 2013, Volume: 39, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2013
Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future oncology (London, England), 2013, Volume: 9, Issue:11 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2013
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine	2014
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines	2014
Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain. Cancer letters, 2015, Mar-28, Volume: 358, Issue:2 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease Management; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neural Stem Cells; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2015
[Systemic treatment of brain metastases from breast cancer]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:1 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Genes, erbB-2; Humans; Lapatinib; Medicine; Molecular Targeted Therapy; Patient Care Team; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2015
HER2-positive metastatic breast cancer: a changing scenario. Critical reviews in oncology/hematology, 2015, Volume: 95, Issue:1 Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2015
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? Current oncology reports, 2015, Volume: 17, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Delivery Systems; Female; Humans; Immunoconjugates; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab	2015
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nature clinical practice. Oncology, 2009, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2	2009
[Advances in research on treatment of breast cancer with lapatinib]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:5 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2	2008
Treatment of brain metastases in patients with HER2+ breast cancer. Advances in therapy, 2009, Volume: 26 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Incidence; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab	2009
Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Critical reviews in oncology/hematology, 2010, Volume: 75, Issue:2 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2	2010
[Lapatinib treatment-option in trastuzumab-resistant breast cancer]. Magyar onkologia, 2009, Volume: 53, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome	2009
[Management of metastatic HER2-positive breast cancer: present and future]. Bulletin du cancer, 2010, Volume: 97, Issue:3 Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles	2010
Systemic treatment in breast-cancer patients with brain metastasis. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:7 Topics: Animals; Anticonvulsants; Antineoplastic Agents; Biological Products; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lapatinib; Quinazolines	2010
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Current opinion in obstetrics & gynecology, 2011, Volume: 23, Issue:1 Topics: Angiogenesis Modulating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab	2011
[Her2 positive breast cancer: practices]. Bulletin du cancer, 2011, Volume: 98, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Heart; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab	2011
Role of chemotherapy on brain metastasis. Progress in neurological surgery, 2012, Volume: 25 Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines	2012
Targeted therapy in brain metastasis. Current opinion in oncology, 2012, Volume: 24, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Humans; Ipilimumab; Lapatinib; Molecular Targeted Therapy; Neovascularization, Pathologic; Quinazolines	2012
New insights and emerging therapies for breast cancer brain metastases. Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab	2012
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]. Bulletin du cancer, 2013, Jan-01, Volume: 100, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab	2013
[Breast cancer and Her-2]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2007

Trials

23 trial(s) available for lapatinib and Benign Neoplasms, Brain

Article	Year
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clinical colorectal cancer, 2020, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain; Brain Neoplasms; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lapatinib; Magnetic Resonance Imaging; Male; Middle Aged; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Trastuzumab	2020
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro-oncology, 2021, 03-25, Volume: 23, Issue:3 Topics: Adolescent; Adult; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Ependymoma; Humans; Lapatinib; Prospective Studies; Spinal Cord Neoplasms; Temozolomide	2021
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of neuro-oncology, 2017, Volume: 134, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome	2017
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Journal of neuro-oncology, 2017, Volume: 134, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome	2017
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer discovery, 2013, Volume: 3, Issue:5 Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays	2013
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2013
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome	2013
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Trastuzumab; Treatment Outcome	2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast cancer research and treatment, 2013, Volume: 142, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2013
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study. Journal of the Egyptian National Cancer Institute, 2014, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2014
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. Anticancer research, 2015, Volume: 35, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2015
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Adult; Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Canada; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine	2015
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2	2009
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cytochrome P-450 CYP3A; Enzyme Induction; ErbB Receptors; Female; Glioblastoma; Humans; Lapatinib; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2	2010
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult	2010
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. Journal of neuro-oncology, 2011, Volume: 105, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan	2011
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC cancer, 2012, Jul-28, Volume: 12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome	2012
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. International journal of clinical oncology, 2013, Volume: 18, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2013
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. The Lancet. Oncology, 2013, Volume: 14, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2	2013
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. Journal of neurology, 2013, Volume: 260, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide	2013
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie Breast cancer (Tokyo, Japan), 2014, Volume: 21, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome	2014
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-15, Volume: 19, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides	2013
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2008

Other Studies

67 other study(ies) available for lapatinib and Benign Neoplasms, Brain

Article	Year
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain. Scientific reports, 2021, 10-15, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Carriers; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2	2021
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer. Scientific reports, 2022, 02-16, Volume: 12, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Injections, Intravenous; Lapatinib; Mice; Micelles; Paclitaxel; Peptides; Tumor Cells, Cultured	2022
Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 08-02, Volume: 28, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Central Nervous System; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Receptor, ErbB-2	2022
Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience. JCO global oncology, 2022, Volume: 8 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab	2022
Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases. ESMO open, 2022, Volume: 7, Issue:6 Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib	2022
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Breast (Edinburgh, Scotland), 2023, Volume: 69 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab	2023
Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process. Oncology, 2023, Volume: 101, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Trastuzumab	2023
Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report. The breast journal, 2020, Volume: 26, Issue:7 Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2	2020
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis. Cancer research and treatment, 2020, Volume: 52, Issue:4 Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; China; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab; Vinorelbine; Young Adult	2020
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS computational biology, 2018, Volume: 14, Issue:1 Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Lapatinib; Logistic Models; Maximum Tolerated Dose; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines	2018
Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity. Scientific reports, 2018, 01-10, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays	2018
Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. Clinical breast cancer, 2018, Volume: 18, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Trastuzumab	2018
Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro-oncology, 2019, 05-06, Volume: 21, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Prognosis; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate	2019
Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. Journal of neurosurgery, 2019, 02-08, Volume: 132, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Middle Aged; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate	2019
Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. The Journal of international medical research, 2019, Volume: 47, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gallbladder Neoplasms; Gene Amplification; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2; Trastuzumab	2019
For breast cancer patients with brain mets, new drug combo may be option. Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Treatment Outcome	2012
Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:9 Topics: Brain Neoplasms; Female; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2013
Prognostic factors of brain metastases from breast cancer: impact of targeted therapies. Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Humans; Intracranial Hypertension; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Quinazolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult	2013
[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain]. Voprosy onkologii, 2013, Volume: 59, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Up-Regulation	2013
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer research, 2013, Sep-15, Volume: 73, Issue:18 Topics: Animals; Apoptosis; Blood-Brain Barrier; Blotting, Western; Brain; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cells, Cultured; Electric Impedance; Endothelium, Vascular; ErbB Receptors; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays	2013
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer biology & therapy, 2013, Oct-01, Volume: 14, Issue:10 Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays	2013
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy. Anticancer research, 2013, Volume: 33, Issue:11 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab	2013
In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles. Current pharmaceutical biotechnology, 2014, Volume: 14, Issue:12 Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Glioma; Injections, Intravenous; Lapatinib; Lethal Dose 50; Lipids; Male; Mice, Inbred ICR; Nanoparticles; Organ Specificity; Particle Size; Quinazolines; Rats, Sprague-Dawley; Solubility; Surface Properties; Tablets; Tissue Distribution	2014
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2014
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:4 Topics: Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2	2014
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. Journal of cellular physiology, 2015, Volume: 230, Issue:1 Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response	2015
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-oncology, 2015, Volume: 17, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines	2015
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Molecular cancer therapeutics, 2014, Volume: 13, Issue:12 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays	2014
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. Breast cancer research and treatment, 2015, Volume: 149, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab	2015
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis? Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Proliferation; Central Nervous System; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2	2015
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Gene Knockdown Techniques; Glucuronidase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection; Tumor Burden; Xenograft Model Antitumor Assays	2015
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. Anti-cancer drugs, 2015, Volume: 26, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab	2015
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Retreatment; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult	2015
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction	2015
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nature communications, 2015, Nov-04, Volume: 6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab	2015
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast cancer research and treatment, 2016, Volume: 155, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Trastuzumab	2016
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. Cancer research, 2016, 04-15, Volume: 76, Issue:8 Topics: Animals; Brain Neoplasms; Carbazoles; DNA-Binding Proteins; Glioblastoma; High Mobility Group Proteins; Humans; Lapatinib; Mice; Quinazolines; Transcriptional Elongation Factors	2016
Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget, 2016, Jun-07, Volume: 7, Issue:23 Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Drug Carriers; Drug Compounding; Drug Stability; Female; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Phosphatidylcholines; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Tissue Distribution; Triple Negative Breast Neoplasms	2016
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity. PloS one, 2016, Volume: 11, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Doxazosin; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Lapatinib; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Tumor Suppressor Protein p53	2016
Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer, 2017, Jun-15, Volume: 123, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; ErbB Receptors; Female; Humans; Lapatinib; Metastasectomy; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab	2017
As metastasis yields its biological secrets, researchers hope to apply findings. Journal of the National Cancer Institute, 2008, Aug-06, Volume: 100, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab	2008
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. Journal of the National Cancer Institute, 2008, Aug-06, Volume: 100, Issue:15 Topics: Analysis of Variance; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Immunochemistry; Lapatinib; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays	2008
Are volumetric changes of brain metastases the best evaluation of efficacy? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-01, Volume: 26, Issue:31 Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cranial Irradiation; Endpoint Determination; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Treatment Outcome	2008
Unilateral taxane-induced onychopathy in a patient with a brain metastasis. Dermatology online journal, 2009, Mar-15, Volume: 15, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine	2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science signaling, 2009, Dec-15, Volume: 2, Issue:101 Topics: Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Fatty Acids; Gene Knockdown Techniques; Glioblastoma; Humans; Hydrolysis; Lapatinib; Lipogenesis; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Sterol Regulatory Element Binding Protein 1	2009
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. British journal of cancer, 2010, Mar-16, Volume: 102, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom	2010
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Young Adult	2011
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. International journal of clinical oncology, 2011, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Mastectomy; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Skin Neoplasms	2011
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? Expert review of anticancer therapy, 2011, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib	2011
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharmaceutical research, 2012, Volume: 29, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Injections, Intravenous; Lapatinib; Mice; Quinazolines; Receptor, ErbB-2; Up-Regulation	2012
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer discovery, 2011, Volume: 1, Issue:5 Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Death; Cholesterol; ErbB Receptors; Glioblastoma; HeLa Cells; Humans; Lapatinib; Liver X Receptors; Mice; Mice, SCID; Orphan Nuclear Receptors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Up-Regulation	2011
Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future oncology (London, England), 2012, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer discovery, 2012, Volume: 2, Issue:5 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines	2012
[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Hydrocephalus; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Ventriculoperitoneal Shunt	2012
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). Oncology, 2012, Volume: 83, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Turkey	2012
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. British journal of cancer, 2012, Sep-25, Volume: 107, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult	2012
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location. Journal of the National Comprehensive Cancer Network : JNCCN, 2012, Volume: 10, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cystadenocarcinoma, Mucinous; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factors; Young Adult	2012
OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer biology & therapy, 2012, Volume: 13, Issue:14 Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Benzoquinones; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Genes, erbB-1; Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Lipids; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides	2012
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America, 2012, Nov-06, Volume: 109, Issue:45 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Death; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Female; Gene Amplification; Humans; Killer Cells, Natural; Lapatinib; Mice; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays	2012
Primary systemic treatment of breast-cancer brain metastases. The Lancet. Oncology, 2013, Volume: 14, Issue:1 Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines	2013
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction	2012
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report. Onkologie, 2012, Volume: 35, Issue:12 Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Kidney Neoplasms; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2012
Brain metastases from HER2-positive breast cancer. The Lancet. Oncology, 2013, Volume: 14, Issue:1 Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines	2013
Brain metastases from HER2-positive breast cancer. The Lancet. Oncology, 2013, Volume: 14, Issue:1 Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines	2013
Brain metastases from HER2-positive breast cancer - authors' reply. The Lancet. Oncology, 2013, Volume: 14, Issue:1 Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines	2013
Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer. Journal of neuro-oncology, 2013, Volume: 112, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate	2013
Targeting HER2 in brain metastases from breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-15, Volume: 9, Issue:15 Topics: Animals; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Rats; Rats, Nude; Receptor, ErbB-2	2003